Tempus to Present Six Abstracts Accepted at the 2026 Connective Tissue Oncology Society Annual Meeting

On November 11, 2026 Tempus AI, Inc. (NASDAQ: TEM) reported that six abstracts (including three oral presentations) will be presented at the 2026 Connective Tissue Oncology Society (CTOS) Annual Meeting taking place November 18–21 in Seoul. At this year’s meeting, Tempus will present clinical research on rare mesenchymal tumors, highlighting how advances in molecular diagnosis and classification are unlocking new treatment options.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

This research leverages Tempus’ expansive, de-identified multimodal library, which includes a cohort of 45,085 real-world patients across 615 rare and ultra-rare cancer types. Within this comprehensive repository, sarcomas are among the most well-represented cancer types. This deep data foundation directly enabled the clinical findings being presented at CTOS, demonstrating the power of comprehensive multimodal profiling—including DNA matched tumor/normal sequencing, whole transcriptomic analysis, and digital pathology informatics—to reveal actionable insights.

"In rare diseases, such as sarcoma, small patient datasets make uncovering insights exceptionally challenging, which is where Tempus’ robust dataset brings critical value," said Ezra Cohen M.D., Chief Medical Officer of Oncology at Tempus. "Importantly, Tempus is dedicated through its Orphan Disease Program to providing solutions to the inherent barriers in rare cancers, and to helping physicians develop and tailor therapies more precisely."

Oral Presentations

Thursday, November 19, 2026 | 2:15 PM – 3:15 PM KST

Melanoma-Associated Antigen A4 (MAGE-A4) mRNA Expression and Tumor Immune Micro-Environment (TIME) as Biomarkers in Sarcoma: A Real-World Clinicogenomic Study
Friday, November 20, 2026 | 4:15 PM – 5:15 PM KST

Distinct DNA Damage Response (DDR) Transcriptional Signature is Enriched in a Subset of SDH-Deficient GIST: Implications for Temozolomide Sensitivity
Transcriptomic Subtyping of 1,490 GIST Patients Identifies Prognostic Risk Groups Superior to Clinical and Molecular Variables
Poster Presentations

Transcriptional Programs Associated with Response to Pazopanib in Metastatic Bone and Soft Tissue Sarcoma
Molecular and Genomic Characteristics of Desmoplastic Small Round Cell Tumor
Improving Germline Variant Detection in Sarcoma via Matched Tumor/Normal Sequencing: A Real-World Analysis of 9,025 Patients

(Press release, Tempus, NOV 11, 2026, View Source [SID1234674622])

Innate Pharma to Host In-Person and Virtual Event on IPH4502 on November 18, 2026

On November 11, 2026 Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) ("Innate" or the "Company") reported that it will host an event focused on IPH4502, its proprietary Nectin-4 ADC. The event will be held in person and virtually on Wednesday, November 18, 2026 at 11:00 AM ET / 4:00 PM GMT, in London, at the IET London, Savoy Place.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Professor Yohann Loriot, M.D., Ph.D. (Gustave Roussy) will join company management to discuss Phase 1 clinical data from the IPH4502 dose-escalation study being presented at the 2026 EORTC-NCI-AACR (Free EORTC-NCI-AACR Whitepaper) (ENA) Symposium.

The event will include a review of the Phase 1 study’s safety, pharmacokinetic and antitumor activity findings, along with a discussion of the current treatment landscape and unmet medical need in urothelial cancer. Professor Loriot will provide his clinical perspective, while Innate management will discuss the scientific rationale for IPH4502 and next steps in its clinical development.

A live question-and-answer session will follow the formal presentations.

Event details

Event: IPH4502 Phase 1 clinical data and development outlook
Date and time: November 18, 2026 at 11:00 a.m. ET / 4:00 p.m. GMT
Location: IET London, Savoy Place, 2 Savoy Place, London WC2R 0BL, United Kingdom
To register for in person participation or virtual access, click here.
A replay will be available in the investors section of Innate Pharma website after the event.

About Professor Yohann Loriot, M.D., Ph.D.

Professor Yohann Loriot is a medical oncologist and Professor of Medicine at Gustave Roussy, specializing in genitourinary cancers, with a particular focus on bladder cancer. He serves as Deputy Head of the Department of Therapeutic Innovation and Early Drug Development (DITEP) and coordinates the UNLOCK program, dedicated to understanding mechanisms of sensitivity and resistance to innovative cancer therapies.

He holds both a Medical Degree and a PhD in Anticancer Pharmacology and teaches at Paris-Saclay University. His research focuses on the development of novel therapeutic strategies and the identification of mechanisms of treatment resistance in solid tumors, particularly urothelial and prostate cancers.

Professor Loriot has authored more than 300 peer-reviewed scientific publications and is an active member of several leading international scientific societies, including ESMO (Free ESMO Whitepaper), ASCO (Free ASCO Whitepaper) and AACR (Free AACR Whitepaper). He also leads the EORTC Urological Tumours Group and contributes to the development of European clinical guidelines in bladder cancer.

Scientific expert disclosure

Professor Yohann Loriot will participate as guest speaker and Gustave Roussy will receive compensation for his participation in the event, which doesn’t constitute an endorsement of the investigational product or a recommendation for its use.

About IPH4502

IPH4502 is Innate Pharma’s proprietary Nectin-4 antibody-drug conjugate (ADC), built on three differentiated components. The payload is exatecan, a potent topoisomerase I inhibitor, with the potential to overcome key limitations associated with monomethyl auristatin E (MMAE)-based ADCs, including multidrug resistance protein 1 (MDR1)-mediated resistance, and without the need for CYP2D6 genotyping. IPH4502 incorporates a proprietary stable linker designed to slow the release of free exatecan into the circulation. The binder is a proprietary humanized anti-Nectin-4 antibody with high affinity and a distinct, non-overlapping epitope compared with enfortumab vedotin (EV). In preclinical studies, IPH4502 demonstrated anti-tumor activity in EV-resistant tumor models and in tumors with low and heterogeneous Nectin-4 expression, supporting its potential applicability across solid tumor types beyond urothelial carcinoma (UC). IPH4502 is currently being evaluated in the Phase 1 IPH4502-101 study (NCT06781983) in patients with advanced solid tumors known to express Nectin-4.

IPH4502 is currently under clinical development and has not received marketing authorization in the European Union or approval from the U.S. Food and Drug Administration (FDA). Its safety and efficacy have not been established for any commercial use. The product is not available for commercial distribution.

(Press release, Innate Pharma, NOV 11, 2026, View Source [SID1234674623])

Faeth Therapeutics to Participate in Upcoming November Investor Conferences

On November 11, 2026 Faeth Therapeutics (Nasdaq: FTH), a clinical-stage oncology company developing multi-node therapies for cancer patients, including its lead program PIKTOR, reported that management will participate in the following upcoming investor conferences:

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Guggenheim 3rd Annual Healthcare Innovation Conference
Wednesday, November 11, 2026
1×1 investor meetings
Boston, MA
Jefferies Global Healthcare Conference in London
Tuesday, November 17, 2026
Presentation at 8:30 AM GMT
London, UK
Webcast Link

Live webcasts of the presentation and fireside chats can be accessed via the Events and Presentations section of the Faeth website at investors.faeththerapeutics.com. Replays will be available for approximately 90 days following the event.

(Press release, Faeth Therapeutics, NOV 11, 2026, View Source [SID1234674608])

Oncolytics Biotech® Announces Clinical Supply Agreement to Evaluate Pelareorep in Combination with LOQTORZI® (toripalimab-tpzi) in Squamous Cell Anal Carcinoma

On November 11, 2026 Oncolytics Biotech Inc. (Nasdaq: ONCY) ("Oncolytics" or the "Company"), a clinical-stage immunotherapy company developing pelareorep, reported that it has entered into a clinical supply agreement with Coherus Oncology, Inc. ("Coherus") to evaluate Oncolytics’ investigational oncolytic virus immunotherapy, pelareorep, in combination with Coherus’ next-generation PD-1 inhibitor, LOQTORZI (toripalimab-tpzi), in a clinical study in patients with squamous cell anal carcinoma ("SCAC").

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The study is expected to be conducted at a premier cancer center in the United States, which will be named once the study commences, and is anticipated to begin in the first quarter of 2027. It is expected to enroll patients who have progressed on the current standard-of-care first-line treatment of chemotherapy and checkpoint inhibition. Importantly, there is no approved therapy for second-line patients in this indication.

Under the terms of the clinical supply agreement, Coherus will provide LOQTORZI to Oncolytics, which is expected to partner with the institution sponsoring the planned clinical study.

"This agreement supports a focused clinical evaluation of pelareorep with a marketed PD-1 inhibitor in a difficult-to-treat patient population," said Jared Kelly, Chief Executive Officer of Oncolytics. "The planned study is designed to build upon the previous efficacy signals pelareorep has shown in second-line or later SCAC patients while getting data in a patient population that has progressed on the new first-line standard of care. If the results are supportive, we believe SCAC could provide an important first step toward evaluating this combination more broadly across HPV-associated cancers."

Rationale for the Pelareorep and Toripalimab Combination

Pelareorep is designed to activate toll-like receptor 3, stimulating innate and adaptive antitumor immune responses, and to promote the formation of tertiary lymphoid structures within the tumor, which have been associated with improved responses to checkpoint inhibitor therapy. Through these mechanisms, pelareorep promotes tumor-directed T-cell activation and infiltration and induces inflammatory signaling within the tumor microenvironment. Recent translational data presented at the Society for Immunotherapy of Cancer (SITC) (Free SITC Whitepaper) Annual Meeting showed that pelareorep combined with a checkpoint inhibitor increases human papillomavirus ("HPV")-16-specific T cell clones and tumor-infiltrating lymphocyte clones in SCAC patients. Toripalimab blocks the PD-1 pathway, a mechanism tumors can use to suppress activated T cells. The planned study will evaluate whether pelareorep-mediated immune activation can enhance the antitumor activity of PD-1 blockade in SCAC patients who have progressed on chemo-immunotherapy treatment.

SCAC is an HPV-associated cancer with limited treatment options for patients whose disease progresses after available therapy. Because HPV-associated tumors express viral antigens that may provide recognizable immune targets, the SCAC study may also inform a potential broader development strategy across HPV-associated cancers.

About Pelareorep
Pelareorep is an intravenously delivered, systemically active, investigational immunotherapy with a dual mechanism of action that selectively replicates in tumor cells while activating both innate and adaptive anti-tumor immune responses, including the upregulation of key inflammatory cytokines resulting in the formation of tertiary lymphoid structures and the expansion of tumor-infiltrating lymphocytes. It has been administered to over 1,200 patients, and clinical studies have demonstrated pelareorep’s potential to enhance the activity of checkpoint inhibitors and other anti-cancer therapies across multiple solid tumor types.

About Toripalimab
LOQTORZI (toripalimab-tpzi) is a next-generation PD-1 inhibitor and is the only available FDA-approved treatment indicated in combination with chemotherapy for recurrent or metastatic nasopharyngeal carcinoma. It is also being developed for additional tumor types with the goal of serving as a PD-1 inhibitor backbone for future treatment combinations that may extend survival for patients.

(Press release, Oncolytics Biotech, NOV 11, 2026, View Source [SID1234674624])

Autolus Therapeutics Reports Third Quarter 2026 Financial Results and Business Updates

On November 10, 2026 Autolus Therapeutics plc (Nasdaq: AUTL), a commercial-stage biopharmaceutical company developing, manufacturing and delivering next-generation programmed T cell therapies and candidates, reported its operational and financial results for the third quarter ended September 30, 2026.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"We delivered another strong quarter of AUCATZYL revenue, primarily driven by growth within existing authorized treatment centers as physicians gain positive experience with the therapy, and supported by real-world data reported through the ROCCA consortium. Importantly, we also continue to improve the gross margin, with strong execution on manufacturing efficiency initiatives," said Dr. Christian Itin, Chief Executive Officer of Autolus.

Dr. Itin added, "AUCATZYL’s performance in adult r/r B-ALL is a key near-term value driver. Longer term, we believe expanding obe-cel across all stages of ALL and into autoimmune indications offers meaningful opportunities for scalable growth, leveraging its favorable profile and Autolus’ proven manufacturing and commercial capabilities. We look forward to autoimmune program data presentations at upcoming key medical meetings."

Product and Pipeline Updates:

AUCATZYL
Autolus reported net product revenue of $41.2 million for the three months ended September 30, 2026, compared to $21.1 million for the same period the prior year. Net revenues were primarily driven by increasing product demand both within existing treatment centers and expansion into new centers, supplemented by contribution from UK sales.
Obe-cel in pediatric r/r B-ALL
The Phase 2 portion of the ongoing CATULUS trial of obe-cel in pediatric patients with relapsed or refractory B-cell precursor ALL (r/r B-ALL) is on track and data are expected to be reported at the end of 2027.
Obe-cel in lupus
Updated data from the ongoing Phase 1 CARLYSLE trial in patients with severe refractory systemic lupus erythematosus (srSLE) will be presented in a poster at the American College of Rheumatology (ACR) Annual Meeting, today, November 10, 2026. These data will include safety and efficacy results with up to 25 months follow-up in adult patients and ≥3 months follow-up in adolescent patients.
LUMINA, the pivotal Phase 2 study of obe-cel in patients with refractory lupus nephritis (LN) continues enrolling in five countries and the Company expects to report data in 2028.
On September 9, 2026, the U.S. Food and Drug Administration (FDA) granted regenerative medicine advanced therapy (RMAT) designation to obe-cel for the treatment of SLE and LN. RMAT is designed to accelerate the development and regulatory review of regenerative medicine therapies, including cell therapies, intended to treat serious or life-threatening diseases.
Obe-cel in progressive multiple sclerosis
KOL feedback at the ACTRIMS/ECTRIMS meeting in late October emphasized that initial clinical activity and biomarker data seen across CAR T programs are encouraging but will require longer follow up to judge the clinical benefit in progressive MS patients. Considering this feedback, Autolus plans to move the first data presentation to the ECTRIMS Global meeting in October 2027. At that time, the Company expects to have 12 months or more follow-up for the initial 12 patients dosed, and data in up to 24 patients total. Lymphodepletion with both FLu/Cy as well as bendamustine is being evaluated.

AUTO8 in Light-Chain Amyloidosis
The Phase 1 ALARIC trial evaluating AUTO8 in light-chain amyloidosis is ongoing and initial data are expected to be reported at ASH (Free ASH Whitepaper) in December 2026.

Outlook:
Autolus now expects full-year 2026 AUCATZYL net product revenue to be at or exceeding the upper end of $150 million from the prior guidance.

Based on current operating plans, including anticipated AUCATZYL net revenues and proceeds of the combined first and second tranches totaling $100 million from the Perceptive credit facility, Autolus expects that its current and projected cash, cash equivalents and marketable securities will be sufficient to fund the Company’s operations into Q2 2028.

Summary of Anticipated News Flow:

Longer-term follow up data from CARLYSLE trial in patients with severe refractory systemic lupus erythematosus ACR 2026
November 10, 2026
Initial clinical data from ALARIC Phase 1 trial in patients with light-chain amyloidosis ASH 2026
December 12, 2026
Initial clinical data from BOBCAT Phase 1 trial in patients with progressive MS October 2027
Phase 2 data from CATULUS trial in patients with pediatric r/r B-ALL By year-end 2027
Phase 2 data from LUMINA trial in patients with LN In 2028

Financial Results for the Quarter Ended September 30, 2026
Product revenue, net increased to $41.2 million for the three months ended September 30, 2026, compared to $21.1 million the same period in 2025.

Cost of sales decreased to $17.9 million for the three months ended September 30, 2026, compared to $28.6 million the same period in 2025. Gross margin1 was 57% in the third quarter of 2026, increasing from 55% in the second quarter of 2026, and a negative gross margin in the same period in 2025. The improvement in gross margin over the prior year was primarily driven by a reduction in manufacturing cost per batch, reflecting increased volumes and the ongoing operational efficiency initiatives, and lower inventory reserves and write-offs compared to the same period in the prior year.

Research and development expenses increased to $30.9 million for the three months ended September 30, 2026, compared to $27.9 million in the same period in 2025. This change was primarily due to an increase in clinical manufacturing supply costs driven by clinical development activities, partially offset by a decrease in salaries and other employment-related costs.

Selling, general and administrative expenses decreased to $35.9 million for the three months ended September 30, 2026, compared to $36.3 million in the same period in 2025. This decrease was primarily due to salaries, other employment-related costs and professional fees supporting commercialization activities in the US and UK.

Loss from operations for the three months ended September 30, 2026, was $43.5 million, as compared to $71.6 million for the same period in 2025.

Net loss was $55.1 million for the three months ended September 30, 2026, compared to $79.1 million for the same period in 2025. Basic and diluted net loss per ordinary share for the three months ended September 30, 2026, was $(0.21), compared to basic and diluted net loss per ordinary share of $(0.30) for the same period in 2025.

Cash, cash equivalents and marketable securities at September 30, 2026, totaled $248.4 million, as compared to $201.6 million at June 30, 2026. The increase was primarily driven by net cash inflows from the senior secured note facility from Perceptive Advisors.

Selected Consolidated Statements of Operations and Comprehensive Loss Data
(In thousands, except share and per share amounts)

Three Months Ended
September 30,
Nine Months Ended
September 30,
2026
2025
2026
2025
Revenue:
Product revenue, net $ 41,238 $ 21,144 $ 113,128 $ 51,049
License revenue — 50 17 50
Total revenue, net 41,238 21,194 113,145 51,099
Cost and operating expenses:
Cost of sales (17,927 ) (28,643 ) (62,963 ) (71,039 )
Research and development expenses, net (30,900 ) (27,892 ) (80,008 ) (82,056 )
Selling, general and administrative expenses (35,946 ) (36,280 ) (117,060 ) (96,082 )
Loss from operations (43,535 ) (71,621 ) (146,886 ) (198,078 )
Other (expense) income:
Total other (expenses) income, net (12,045 ) (6,965 ) (18,075 ) 4,037
Net loss before income tax (55,580 ) (78,586 ) (164,961 ) (194,041 )
Income tax benefit (expense) 489 (532 ) (839 ) (3,155 )
Net loss (55,091 ) (79,118 ) (165,800 ) (197,196 )
Other comprehensive income (loss):
Foreign currency exchange translation adjustment 484 (5,868 ) (108 ) 23,790
Unrealized holding (losses) gains on available-for-sale debt securities, net of tax of $0, $0, $0 and $0, respectively (6 ) 86 (159 ) 464
Total other comprehensive income (loss), net of tax 478 (5,782 ) (267 ) 24,254
Total comprehensive loss $(54,613 ) $(84,900 ) $(166,067 ) $(172,942 )

Basic and diluted net loss per ordinary share $ (0.21 ) $ (0.30 ) $ (0.62 ) $ (0.74 )
Weighted-average basic and diluted ordinary shares 266,203,656 266,141,431 266,168,856 266,136,518

Financial Results for the Period Ended September 30, 2026
Selected Consolidated Balance Sheet Data
(In thousands)

September 30, December 31,
2026
2025
Assets
Cash and cash equivalents $ 245,405 $ 104,132
Marketable securities – Available-for-sale debt securities $ 2,972 $ 196,578
Total current assets $ 366,784 $ 435,915
Total assets $ 523,059 $ 589,068
Liabilities and shareholders’ equity
Total current liabilities $ 98,647 $ 73,440
Total liabilities $ 495,663 $ 410,939
Total shareholders’ equity $ 27,396 $ 178,129

Conference Call
Management will host a conference call and webcast today at 8:30am EDT/1:30pm GMT to discuss the company’s financial results. Conference call participants should pre-register using this link to receive the dial-in numbers and a personal PIN, which are required to access the conference call. A simultaneous audio webcast and replay will be accessible on the events section of Autolus’ website at View Source

(Press release, Autolus, NOV 10, 2026, View Source [SID1234674552])